Metabolic Alterations driven by PFKFB3 upregulation confer Resistance to Trastuzumab in HER2-Positive Breast Cancer.
Roos Vincken, Samuel Tanner Pasco, Veronica Steri…·Ana Ruiz-Sáenz
This study identifies PFKFB3 upregulation as a driver of trastuzumab resistance in HER2+ breast cancer through metabolic rewiring and reduced ADCC, with clinical correlations to poor survival.